Minimally Invasive Treatment for Facial Injection Infection

Over the past decade, the demand for facial filler injections has increased significantly due to their rapid onset and convenience compared to surgical procedures. The number of people opting for facial implants has grown in tandem with the incidence of complications. The probability of infection following injection ranges from 0.04% to 0.2%. Infected patients may exhibit local symptoms, including redness, pain, and pus accumulation. This study evaluated the safety and efficacy of triamcinolone acetonide and 5-fluorouracil for treating abscesses following facial filler injections to control infection. Seven patients with a history of unknown facial fillings combined with infection were included. The treatment method involved performing abscess aspiration at the infected site, injecting 0.7% triamcinolone acetonide and 0.42% 5-fluorouracil into the same area. The infection was controlled, and swelling disappeared within an average of 13±2.94 days. No recurrence was observed during the average follow-up period of 3.57±1.72 months. Ultrasound results indicated a reduction in the padding area, with the disappearance of blood flow signals and tissue swelling. The results demonstrated that abscess aspiration combined with drug injection was feasible and effective for treating facial abscess infections following facial filler injections. These findings can serve as a reference for the clinical treatment of facial infections post-filler injections. Level 2-cohort study.